Goldman Sachs increased its investment in Sellas Life Sciences by acquiring 29,122 additional shares. This purchase raises the firm's total stake by 5.2% to 585,035 shares. The total position is valued at approximately $8.64 million.
The investment precedes the final readout of the Phase 3 REGAL trial. This study evaluates Galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML).
The trial has recorded 78 of the 80 events required for final analysis. Sellas will initiate database lock and unblinding once the 80th event occurs. The company will then release topline results for the trial.